Contents 3 min read

Claim and source comparison

Selected human-trial abstracts, publisher sections on plasma kinetics and FDA GRN 209 were compared. Experiments without verified randomization in the accessed source have a separate label. Not a full clinical review or independent medical approval.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human randomized controlled trial

Kimura et al. (2007) examined heart-rate and salivary IgA responses to arithmetic stress with 200 mg L-theanine in 12 men; this was not an EEG experiment. Nobre et al. (2008) measured resting EEG alpha activity with 50 mg; this alone does not establish faster reactions or clinical anxiety treatment.

Heart rate, salivary IgA and resting EEG are different measures. They do not directly establish increased human brain GABA, general attention superiority or anxiety-disorder treatment; limits of small, acute experiments remain.

Source 1 · Source 2 · Abstract read

Human controlled trial; randomization not verified

Owen et al. (2008) studied 50 mg caffeine plus 100 mg L-theanine in 27 people; some attention-switching measures improved. The study used behavioral tests; it does not prove an ideal 2:1 ratio for everyone or guaranteed prevention of caffeine adverse effects.

A selected-task result does not establish an ideal ratio for everyone, long-term benefit or prevention of caffeine effects such as palpitations/anxiety. The accessed abstract does not verify randomization, so it is labelled a controlled human trial.

Source 3 · Abstract read

Human randomized controlled trial

Lyon et al. (2011) compared 400 mg/day Suntheanine with placebo for six weeks in 98 boys aged 8–12 with ADHD. Actigraphy showed improvements in some sleep-percentage/efficiency measures; sleep latency was unchanged.

Limited to a specific diagnosis, age, sex, product and short duration. This amount is not a personal pediatric dose or adult insomnia treatment; no serious harm in a short trial does not establish long-term safety.

Source 5 · Abstract read

Human pharmacokinetic study

Van der Pijl et al. (2010) studied 25–100 mg L-theanine in tea or aqueous solution in 15 healthy men. A one-compartment model estimated an elimination half-life of approximately 65 minutes and plasma peak time of approximately 50 minutes.

The profile’s approximate one-hour value rounds this plasma estimate. Peak time is not clinical onset; the model does not determine brain levels, effect duration, personal dose or timing. Authors have Unilever affiliations.

Source 6 · Full text read

Regulatory scientific assessment

FDA GRN 209 records a “no questions” response for L-theanine use up to 250 mg per serving in specified food categories. It is not drug-efficacy approval or a recommendation for 250 mg/day supplementation.

GRAS concerns specified products and food uses. This record does not establish long-term supplementation, pregnancy/breastfeeding or combined-use safety with sedatives/blood-pressure medicines; missing interaction records do not prove safety.

Source 7 · Official summary read

Our evidence and source methodology

L-Theanine: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is L-Theanine?

L-theanine is an amino acid found in tea. Small human studies examined stress, sleep and attention with caffeine; treatment of every anxiety condition or prevention of caffeine adverse effects has not been established.

Clinical Evidence

Kimura et al. (2007) examined heart-rate and salivary IgA responses to arithmetic stress with 200 mg L-theanine in 12 men; this was not an EEG experiment. Nobre et al. (2008) measured resting EEG alpha activity with 50 mg; this alone does not establish faster reactions or clinical anxiety treatment.

Heart rate, salivary IgA and resting EEG are different measures. They do not directly establish increased human brain GABA, general attention superiority or anxiety-disorder treatment; limits of small, acute experiments remain.

Owen et al. (2008) studied 50 mg caffeine plus 100 mg L-theanine in 27 people; some attention-switching measures improved. The study used behavioral tests; it does not prove an ideal 2:1 ratio for everyone or guaranteed prevention of caffeine adverse effects.

A selected-task result does not establish an ideal ratio for everyone, long-term benefit or prevention of caffeine effects such as palpitations/anxiety. The accessed abstract does not verify randomization, so it is labelled a controlled human trial.

Lyon et al. (2011) compared 400 mg/day Suntheanine with placebo for six weeks in 98 boys aged 8–12 with ADHD. Actigraphy showed improvements in some sleep-percentage/efficiency measures; sleep latency was unchanged.

Limited to a specific diagnosis, age, sex, product and short duration. This amount is not a personal pediatric dose or adult insomnia treatment; no serious harm in a short trial does not establish long-term safety.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Van der Pijl et al. (2010) studied 25–100 mg L-theanine in tea or aqueous solution in 15 healthy men. A one-compartment model estimated an elimination half-life of approximately 65 minutes and plasma peak time of approximately 50 minutes.

The profile’s approximate one-hour value rounds this plasma estimate. Peak time is not clinical onset; the model does not determine brain levels, effect duration, personal dose or timing. Authors have Unilever affiliations.

Safety and Side Effects

FDA GRN 209 records a “no questions” response for L-theanine use up to 250 mg per serving in specified food categories. It is not drug-efficacy approval or a recommendation for 250 mg/day supplementation.

GRAS concerns specified products and food uses. This record does not establish long-term supplementation, pregnancy/breastfeeding or combined-use safety with sedatives/blood-pressure medicines; missing interaction records do not prove safety.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Research and safety news

  • · Research
    Small blackcurrant blend trial finds selective attention changes in older adults

    A crossover trial analyzed 26 older adults after four-week periods of a blackcurrant, L-theanine and pine-bark blend or placebo. Attention-task false alarms declined, but memory and fatigue findings were not significant after multiple-testing correction; the blend cannot isolate an ingredient.

Sources

  1. Kimura K, et al. (2007). L-Theanine reduces psychological and physiological stress responses. Biological Psychology, 74(1), 39–45. PubMed · PMID 16930802
  2. Nobre AC, et al. (2008). L-Theanine, a natural constituent in tea, and its effect on mental state. Asia Pacific Journal of Clinical Nutrition, 17(S1), 167–168. PubMed · PMID 18296328
  3. Owen GN, et al. (2008). The combined effects of L-Theanine and caffeine on cognitive performance and mood. Nutritional Neuroscience, 11(4), 193–198. PubMed · PMID 18681988
  4. Ritsner MS, et al. (2011). L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. Journal of Clinical Psychiatry, 72(1), 34–42. PubMed · PMID 21208586
  5. Lyon MR, et al. (2011). The effects of L-theanine (Suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. Alternative Medicine Review, 16(4), 348–354. PubMed · PMID 22214254
  6. van der Pijl PC, Chen L, Mulder TPJ. (2010). Human disposition of L-theanine in tea or aqueous solution. Journal of Functional Foods, 2(4), 239–244. https://doi.org/10.1016/j.jff.2010.08.001 Publisher record · DOI · Elsevier
  7. US Food and Drug Administration. GRN No. 209: L-theanine. https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=209 US Food and Drug Administration

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions